Cargando…

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists are used successfully in the treatment of patients with type 2 diabetes as they are associated with low hypoglycemia rates, weight loss and improved glycemic control. This study compared, in the Spanish setting, the cost-effectiveness o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mezquita-Raya, Pedro, Ramírez de Arellano, Antonio, Kragh, Nana, Vega-Hernandez, Gabriela, Pöhlmann, Johannes, Valentine, William J., Hunt, Barnaby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380501/ https://www.ncbi.nlm.nih.gov/pubmed/28224463 http://dx.doi.org/10.1007/s13300-017-0239-6

Ejemplares similares

Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
por: Mezquita Raya, Pedro, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
por: Pérez, Antonio, et al.
Publicado: (2015)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence
por: Raya, Pedro Mezquita, et al.
Publicado: (2019)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
por: Hunt, Barnaby, et al.
Publicado: (2017)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
por: Hunter, Kerry, et al.
Publicado: (2012)

Self-Reported Frequency and Impact of Hypoglycemic Events in Spain
por: Orozco-Beltrán, Domingo, et al.
Publicado: (2014)

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
por: Feher, Michael, et al.
Publicado: (2017)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
por: Vandemark, Collin, et al.
Publicado: (2023)

The Economic Burden of Insulin-Related Hypoglycemia in Spain
por: Parekh, Witesh, et al.
Publicado: (2017)

The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation
por: Xiao, Mochao, et al.
Publicado: (2020)

Erratum to: The Economic Burden of Insulin-Related Hypoglycemia in Spain
por: Parekh, Witesh, et al.
Publicado: (2017)

Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
por: Argüelles-Arias, Federico, et al.
Publicado: (2022)

Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying
por: Marathe, Chinmay S., et al.
Publicado: (2022)

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
por: Pinkney, Jonathan, et al.
Publicado: (2010)

GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome
por: Seppa, Kadri, et al.
Publicado: (2019)

Success story of GLP-1 agonist (Liraglutide) treatment in someone with type 1 diabetes: a life transformed
por: Heald, Adrian H., et al.
Publicado: (2023)

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
por: Noyan-Ashraf, Mohammad Hossein, et al.
Publicado: (2009)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
por: Mezquita-Raya, Pedro, et al.
Publicado: (2015)

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures
por: Gupta, Gaurav, et al.
Publicado: (2017)

The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
por: Que, Qihong, et al.
Publicado: (2019)

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease
por: Zhang, Zijuan, et al.
Publicado: (2023)

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
por: Fonseca, Vivian A., et al.
Publicado: (2012)

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
por: Ratner, R E, et al.
Publicado: (2010)

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
por: Lv, Jing, et al.
Publicado: (2014)

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
por: Ostawal, Amrita, et al.
Publicado: (2016)

Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients
por: Harreiter, Jürgen, et al.
Publicado: (2017)

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014)

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
por: Shaefer, Charles F.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mlqo7oljng0c848f9vtisa5eld